Table of Content

Frequent Abbreviations

0          Executive Summary

1          Target Background: Structure & Function

2          Target Antigen Expression Profile

2.1       Hematologic Malignancies

2.2       Various Solid Tumors

2.3       Lung Cancer

2.4       Pancreatic Cancer

2.5       Colorectal Cancer

2.6       Breast Cancer

2.7       Ovarian Cancer

3          Preclinical Safety of ROR1-Targeted Therapy Candidates

4          Clinical Experience with ROR1-Targeted Drug Modalities

5          Clinical Indications & Patient Populations

5.1       Chronic Lymphocytic Leukemia

5.2       Mantle Cell Lymphoma

5.3       Diffuse Large B-Cell Lymphoma

5.4       Triple Negative Breast Cancer

6          Competitive Landscape & Drug Modalities

6.1       ROR1-Targeted Antibody Drug Conjugates

6.2       T-Cell EngagingAnti-ROR1 Antibodies

6.3       Adoptive Cell Therapy with ROR1-Targeted CAR T-Cells and NK Cells

6.4       ROR1 Small Molecule Inhibitor

7          Drug & Cell Therapy Candidate Profiles

7.1       Naked Antibody

7.2       Antibody-Drug Conjugates

7.3       T-Cell Engaging Bispecific Antibodies

7.4       CAR T-Cells & NK Cells

7.5       Small Molecule Inhibitor

8          Company Profiles

9          References

Tables in the Text

Table 1           Overview of the Number of Cases of ROR1 Overexpression in Hematologic Malignancies

Table 2           Overview of the Number of Cases of ROR1 Overexpression in Solid Tumors

Table 3           Lead and Up-Side Indications of Clinical Studies with ROR1-Targeted Therapy Candidates

Table 4           Overview of Number and R&D Stage of ROR1-Targeted Drug Modalities

Table 5           Pipeline of ROR1-Targeted Antibody-Drug Conjugates in Development

Table 6           Pipeline of T-Cell Engaging ROR1-Targeted Antibodies

Table 7           Pipeline of ROR1-Targeted CAR T-Cells and NK Cells

Table 8           NovalGen’s ROR1-Targeted Drug Modality Pipeline